Skip to main content

Advertisement

SpringerLink
Log in

Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Creed F, Levy R, Bradley L, et al. Psychosocial aspects of functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:295–368.

    Google Scholar 

  2. Thiwan SM, Drossman DA. Treatment of functional GI disorders with psychotropic medicines: a review of evidence with a practical approach. Gastroenterol Hepatol. 2006;2:678–688.

    Google Scholar 

  3. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–1252. doi:10.1056/NEJMoa052964.

    Article  PubMed  CAS  Google Scholar 

  4. Lembo A, Ameen V, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol. 2005;3:717–725. doi:10.1016/S1542-3565(05)00157-6.

    Article  PubMed  Google Scholar 

  5. Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry. 2001;62(Supp 8):38–45. discussion 46–47.

    PubMed  Google Scholar 

  6. Rotem AY, Sperber AD, Krugliak P, Freidman B, Tal A, Tarasiuk A. Polysomnographic and actigraphic evidence of sleep fragmentation in patients with irritable bowel syndrome. Sleep. 2003;26:747–752.

    PubMed  Google Scholar 

  7. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Do the second-generation “atypical neuroleptics” have analgesic properties? A structured evidence-based review. Pain Med. 2004;5(4):359–365. doi:10.1111/j.1526-4637.2004.04054.x.

    Article  PubMed  Google Scholar 

  8. Creswell JW. Research Design. Qualitative, Quantitative and Mixed Methods Approaches. 2nd ed. California: Sage Publications; 2003.

    Google Scholar 

  9. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19–31. doi:10.1016/S0016-5085(03)00669-3.

    Article  PubMed  Google Scholar 

  10. Drossman DA. The functional gastrointestinal disorders and the Rome III process. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:1–29.

    Google Scholar 

  11. Longstreth G, Thompson W, Chey W, Houghton L, et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:487–555.

    Google Scholar 

  12. Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med. 1995;123(10):782–794.

    PubMed  CAS  Google Scholar 

  13. Ringel Y, Drossman DA, Leserman JL, et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology. 2008;134(2):396–404. doi:10.1053/j.gastro.2007.11.011.

    Article  PubMed  Google Scholar 

  14. Whitehead WE, Palsson O, Jones KR. Systematic review of comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140–1156. doi:10.1053/gast.2002.32392.

    Article  PubMed  Google Scholar 

  15. Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol. 2000;95(4):974–980. doi:10.1111/j.1572-0241.2000.01936.x.

    Article  PubMed  CAS  Google Scholar 

  16. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar 1 and bipolar 2 depression: a secondary analysis from a randomized, double blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355–362.

    PubMed  CAS  Google Scholar 

  17. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45(1):17–28. doi:10.1176/appi.psy.45.1.17.

    Article  PubMed  CAS  Google Scholar 

  18. Tarazi FI, Zhang K, Baldessarini RJ. Long term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002;161(3):263–270. doi:10.1007/s00213-002-1016-3.

    Article  CAS  Google Scholar 

  19. Creed F, Guthurie E, Ratcliffe J, et al. Does psychosocial treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry. 2005;39:807–815. doi:10.1111/j.1440-1614.2005.01686.x.

    Article  PubMed  Google Scholar 

  20. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651–1659. doi:10.1053/j.gastro.2003.09.028.

    Article  PubMed  Google Scholar 

  21. Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology. 1996;110:999–1007. doi:10.1053/gast.1996.v110.pm8613034.

    Article  PubMed  CAS  Google Scholar 

  22. Schutters SI, van Megen HJ, Westenberg HG. Efficacy of quetiapine in generalized social anxiety disorder: results from an open label-study. J Clin Psychiatry. 2005;66:540–542.

    Article  PubMed  Google Scholar 

  23. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24:487–494. doi:10.1002/da.20275.

    Article  PubMed  CAS  Google Scholar 

  24. Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999;35(3):193–210.

    CAS  Google Scholar 

  25. McConville B, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61:252–260.

    PubMed  CAS  Google Scholar 

  26. Fass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000;95:1195–1200. doi:10.1111/j.1572-0241.2000.02009.x.

    Article  PubMed  CAS  Google Scholar 

  27. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with post traumatic stress disorder: an open trial of adjuvant therapy. J Clin Psychopharmacol. 2003;23:15–20. doi:10.1097/00004714-200302000-00003.

    Article  PubMed  CAS  Google Scholar 

  28. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004;174:421–429.

    CAS  Google Scholar 

  29. Schreiber S, Getslev V, Backer MM. The atypical neuroleptics clozapine and olanzapine differ regarding their antipsychotic mechanisms and potency. Pharmacol Biochem Behav. 1999;64:75–80. doi:10.1016/S0091-3057(99)00107-0.

    Article  PubMed  CAS  Google Scholar 

  30. Shemo M, Shemo JPD, Anderson M. Beneficial effects of quetiapine treatment in patients with fibromyalgia. J Neuropsychiatry Clin Neurosci. 2003;15:282.

    Google Scholar 

  31. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002;23:526–532. doi:10.1016/S0885-3924(02)00391-3.

    Article  PubMed  CAS  Google Scholar 

  32. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:71–77. doi:10.1016/j.pnpbp.2006.06.023.

    Article  PubMed  CAS  Google Scholar 

  33. Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452. doi:10.1136/ard.2003.011502.

    Article  PubMed  CAS  Google Scholar 

  34. Hellewell JSE, Hands DC, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EP’S than placebo across the full dose range. Schizophr Res. 1998;29:154–155.

    Google Scholar 

  35. Brooke NS, Wiersgalla M, Salzman C. Atypical uses of atypical antipsychotics. Harv Rev Psychiatry. 2005;13:317–339. doi:10.1080/10673220500433148.

    Article  PubMed  Google Scholar 

  36. Drossman DA, Chang L. Psychosocial factors in the care of patients with GI disorders. In: Yamada T, ed. Textbook of Gastroenterology, Chapter 29. Philadelphia: Lippincott; 2003:636–654.

    Google Scholar 

Download references

Acknowledgments

Supported by the Gastrointestinal Biopsycho-social Research Center at UNC, NIH R24Dk067674.

Author information

Authors and Affiliations

  1. Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Campus Box 7080, Chapel Hill, NC, 27599-7080, USA

    Madhusudan Grover, Spencer D. Dorn, Stephan R. Weinland, Christine B. Dalton, Bradley N. Gaynes & Douglas A. Drossman

  2. Department of Internal Medicine, Michigan State University, East Lansing, MI, USA

    Madhusudan Grover

Authors
  1. Madhusudan Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spencer D. Dorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan R. Weinland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine B. Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bradley N. Gaynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Douglas A. Drossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas A. Drossman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grover, M., Dorn, S.D., Weinland, S.R. et al. Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders. Dig Dis Sci 54, 1284–1291 (2009). https://doi.org/10.1007/s10620-009-0723-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-009-0723-6

Keywords

Search

Navigation